Moreno-Gonzalez E, Meneu-Diaz J C, Garcia I, Perez Cerdá F, Abradelo M, Jimenez C, Loinaz C, Gomez R, Gimeno A, Moreno A
Department of General, Digestive, and Abdominal Organs Transplantation, University Hospital 12 de Octubre, Madrid, Spain.
Arch Surg. 2004 Nov;139(11):1189-93. doi: 10.1001/archsurg.139.11.1189.
Combined liver-kidney transplantation is safe (low morbidity and acceptable mortality) and effective in patients with end-stage liver disease. Although refinements in surgical technique have resulted in better patient and allograft outcomes, the negative impact of renal insufficiency on survival in patients undergoing liver transplantation has been widely reported, although some aspects are controversial.
Analysis of the clinical characteristics and outcome in the management of patients undergoing combined liver-kidney transplantation. The end points were operative mortality, morbidity, and long-term survival.
University Hospital 12 de Octubre.
Between May 1986 and December 2001, 820 liver transplantations were performed. There were 16 cases (1.96%) of combined liver-kidney transplantations, which represent the sample of this study.
Mean +/- SD follow-up of 42.2 +/- 29 months: 6 patients died (37.5% mortality rate). There were 4 (25%) hospital deaths within 6 months following surgery and 2 after 6 months (4 sepsis, 1 refractory heart failure, and 1 recurrent hepatitis C virus disease). Univariate analysis related to mortality included age, sex, etiology, preoperative creatinine level, United Network for Organ Sharing status, Child-Pugh score, type of hepatectomy (piggyback), intraoperative blood product administration, and the presence of postoperative complications. The only 2 significant factors were the presence of postoperative complications (P = .01) and the United Network for Organ Sharing status (P = .02). Crude survival rate was 62.5%. Actuarial survival rates were 80%, 71%, and 60% at 1, 3, and 5 years, respectively.
Because end-stage renal disease is not a formal contraindication for liver transplantation, a combined liver-kidney transplantation for adults with end-stage renal disease can be done safely and effectively.
肝肾联合移植对于终末期肝病患者而言是安全的(发病率低且死亡率可接受)且有效。尽管手术技术的改进已带来更好的患者及移植物预后,但肾功能不全对肝移植患者生存的负面影响已被广泛报道,不过某些方面仍存在争议。
对接受肝肾联合移植患者管理中的临床特征及预后进行分析。终点指标为手术死亡率、发病率及长期生存率。
10月12日大学医院。
1986年5月至2001年12月期间共进行了820例肝移植手术。其中有16例(1.96%)肝肾联合移植,构成了本研究的样本。
平均随访时间为42.2±29个月:6例患者死亡(死亡率为37.5%)。术后6个月内有4例(25%)院内死亡,6个月后有2例(4例因败血症、1例因难治性心力衰竭、1例因丙型肝炎病毒复发疾病)。与死亡率相关的单因素分析包括年龄、性别、病因、术前肌酐水平、器官共享联合网络状态、Child-Pugh评分、肝切除术类型(背驮式)、术中血液制品输注情况以及术后并发症的存在与否。仅有的2个显著因素是术后并发症的存在(P = 0.01)和器官共享联合网络状态(P = 0.02)。粗生存率为62.5%。1年、3年和5年的精算生存率分别为80%、71%和60%。
由于终末期肾病并非肝移植的正式禁忌证,对于患有终末期肾病的成人进行肝肾联合移植可安全有效地实施。